Literature DB >> 23402345

Recovery of radiation-induced dry eye and corneal damage by pretreatment with adenoviral vector-mediated transfer of erythropoietin to the salivary glands in mice.

Eduardo M Rocha1, Ana P Cotrim, Changyu Zheng, Paola Perez Riveros, Bruce J Baum, John A Chiorini.   

Abstract

Therapeutic doses of radiation (RTx) causes dry eye syndrome (DES), dry mouth, and as in other sicca syndromes, they are incurable. The aims of this work are as follows: (a) to evaluate a mouse model of DES induced by clinically relevant doses of radiation, and (b) to evaluate the protective effect of erythropoietin (Epo) in preventing DES. C3H female mice were subjected to five sessions of RTx, with or without pre-RTx retroductal administration of the AdLTR2EF1a-hEPO (AdEpo) vector in the salivary glands (SG), and compared with naïve controls at Day 10 (10d) (8 Gy fractions) and 56 days (56d) (6 Gy fractions) after RTx treatment. Mice were tested for changes in lacrimal glands (LG), tear secretion (phenol red thread), weight, hematocrit (Hct), and markers of inflammation, as well as microvessels and oxidative damage. Tear secretion was reduced in both RTx groups, compared to controls, by 10d. This was also seen at 56d in RTx but not AdEpo+RTx group. Hct was significantly higher in all AdEpo+RTx mice at 10d and 56d. Corneal epithelium was significantly thinner at 10d in the RTx group compared with AdEpo+RTx or the control mice. There was a significant reduction at 10d in vascular endothelial growth factor (VEGF)-R2 in LG in the RTx group that was prevented in the AdEpo+RTx group. In conclusion, RTx is able to induce DES in mice. AdEpo administration protected corneal epithelia and resulted in some recovery of LG function, supporting the value of further studies using gene therapy for extraglandular diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23402345      PMCID: PMC3631015          DOI: 10.1089/hum.2012.111

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  37 in total

Review 1.  In vivo gene transfer to salivary glands.

Authors:  B J Baum; B C O'Connell
Journal:  Crit Rev Oral Biol Med       Date:  1999

Review 2.  Mechanisms involved in injury and repair of the murine lacrimal gland: role of programmed cell death and mesenchymal stem cells.

Authors:  Driss Zoukhri
Journal:  Ocul Surf       Date:  2010-04       Impact factor: 5.033

Review 3.  Pterygium: its treatment with beta therapy.

Authors:  Juan Murube
Journal:  Ocul Surf       Date:  2009-01       Impact factor: 5.033

Review 4.  Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise.

Authors:  M Brines; A Cerami
Journal:  Kidney Int       Date:  2006-05-31       Impact factor: 10.612

Review 5.  Oxygen radicals, nitric oxide and human inflammatory joint disease.

Authors:  B Halliwell
Journal:  Ann Rheum Dis       Date:  1995-06       Impact factor: 19.103

6.  Extended transgene expression from a nonintegrating adenoviral vector containing retroviral elements.

Authors:  Changyu Zheng; Joseph M Vitolo; Weitian Zhang; Fumi Mineshiba; John A Chiorini; Bruce J Baum
Journal:  Mol Ther       Date:  2008-03-25       Impact factor: 11.454

7.  Ocular morbidity after radiotherapy of orbital and conjunctival lymphoma.

Authors:  E M Bessell; J M Henk; R A Whitelocke; J E Wright
Journal:  Eye (Lond)       Date:  1987       Impact factor: 3.775

8.  Increased expression of erythropoietin receptor in human pterygial tissues.

Authors:  Satoru Kase; Mitsuhiko Osaki; Xue-Hai Jin; Kazuhiro Ohgami; Kazuhiko Yoshida; Wataru Saito; Shuji Takahashi; Katsuya Nakanishi; Hisao Ito; Shigeaki Ohno
Journal:  Int J Mol Med       Date:  2007-11       Impact factor: 4.101

9.  Effect of x-ray irradiation on lipid peroxide levels in the rat submandibular gland.

Authors:  M Nishi; H Takashima; T Oka; N Ohishi; K Yagi
Journal:  J Dent Res       Date:  1986-07       Impact factor: 6.116

10.  Aspirin prevents diabetic oxidative changes in rat lacrimal gland structure and function.

Authors:  Angélica Gobbi Jorge; Carolina Maria Módulo; Ana Carolina Dias; Alexandre Martins Braz; Rubens Bertazolli Filho; Alceu A Jordão; Jayter Silva de Paula; Eduardo Melani Rocha
Journal:  Endocrine       Date:  2009-02-04       Impact factor: 3.633

View more
  6 in total

Review 1.  Gene therapy for radioprotection.

Authors:  W H Everett; D T Curiel
Journal:  Cancer Gene Ther       Date:  2015-02-27       Impact factor: 5.987

Review 2.  Autoimmunity in the pathogenesis and treatment of keratoconjunctivitis sicca.

Authors:  Katy C Liu; Kyle Huynh; Joseph Grubbs; Richard M Davis
Journal:  Curr Allergy Asthma Rep       Date:  2014-01       Impact factor: 4.806

Review 3.  Advances in salivary gland gene therapy - oral and systemic implications.

Authors:  Bruce J Baum; Ilias Alevizos; John A Chiorini; Ana P Cotrim; Changyu Zheng
Journal:  Expert Opin Biol Ther       Date:  2015-07-06       Impact factor: 4.388

4.  Toward gene therapy for growth hormone deficiency via salivary gland expression of growth hormone.

Authors:  G Z Racz; C Zheng; C M Goldsmith; B J Baum; N X Cawley
Journal:  Oral Dis       Date:  2014-01-13       Impact factor: 3.511

Review 5.  Oxidative Stress in the Protection and Injury of the Lacrimal Gland and the Ocular Surface: are There Perspectives for Therapeutics?

Authors:  Camila Nunes Lemos; Lilian Eslaine Costa Mendes da Silva; Jacqueline Ferreira Faustino; Marina Zilio Fantucci; Adriana de Andrade Batista Murashima; Leidiane Adriano; Monica Alves; Eduardo Melani Rocha
Journal:  Front Cell Dev Biol       Date:  2022-03-11

Review 6.  Application of Animal Models in Interpreting Dry Eye Disease.

Authors:  Jun Zhu; Takenori Inomata; Kendrick Co Shih; Yuichi Okumura; Kenta Fujio; Tianxiang Huang; Ken Nagino; Yasutsugu Akasaki; Keiichi Fujimoto; Ai Yanagawa; Maria Miura; Akie Midorikawa-Inomata; Kunihiko Hirosawa; Mizu Kuwahara; Hurramhon Shokirova; Atsuko Eguchi; Yuki Morooka; Fang Chen; Akira Murakami
Journal:  Front Med (Lausanne)       Date:  2022-02-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.